DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer

Tolkach, Yuri; Zarbl, Romina; Bauer, Simone; Ritter, Manuel; Ellinger, Jörg; Hauser, Stephan; Hüser, Laura; Klauck, Sabine M.; Altevogt, Peter; Sültmann, Holger; Dietrich, Dimo; Kristiansen, Glen

doi:10.1016/j.ajpath.2020.12.014

Cited by 7 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although gene transcription level is usually considered to be negatively correlated with DNA methylation level of promoter in the past, more and more studies support that the high methylation level of promoter can induce gene expression. For example, CD24, the promoter of which exhibited high DNA methylation level, was confirmed overexpressed 67 . Given complex epigenetic regulatory mechanisms, we guess that BEND3 can promote CD24 expression via hypermethylating its promoter, which deserves further research.…”

Section: Discussionmentioning

confidence: 98%

CD24-associated ceRNA network reveals prognostic biomarkers in breast carcinoma

Zhao

Chen

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Breast cancer is one of the most common cancer types which is described as the leading cause of cancer death in women. After competitive endogenous RNA (ceRNA) hypothesis was proposed, this triple regulatory network has been observed in various cancers, and increasing evidences reveal that ceRNA network plays a significant role in the migration, invasion, proliferation of cancer cells. In the current study, our target is to construct a CD24-associated ceRNA network, and to further identify key prognostic biomarkers in breast cancer. Using the transcriptom profiles from TCGA database, we performed a comprehensive analysis between CD24high tumor samples and CD24low tumor samples, and identified 132 DElncRNAs, 602 DEmRNAs and 26 DEmiRNAs. Through comprehensive analysis, RP1-228H13.5/miR-135a-5p/BEND3 and SIM2 were identified as key CD24-associated biomarkers, which exhibited highly significance with overall survival, immune microenvironment as well as clinical features. To sum up the above, the current study constructed a CD24-associated ceRNA network, and RP1-228H13.5/miR-135a-5p/BEND3 and SIM2 axis worked as a potential therapeutic target and a predictor for BRCA diagnosis and prognosis.

show abstract

Section: Discussionmentioning

confidence: 98%

CD24-associated ceRNA network reveals prognostic biomarkers in breast carcinoma

Zhao

Chen

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Tolkach et al found significantly higher levels of DNA methylation in the promoter region of the CD24 (sialoglycoprotein) gene, in tissue samples from PC patients (n = 30) compared to samples from patients with normal prostate (n = 35) and benign prostatic hyperplasia (n = 28) [ 64 , 65 ]. This reflects global changes in DNA methylation as the tumor progresses in prostate cancer.…”

Section: The Role Of Dna Methylation In Prostate Carcinogenesismentioning

confidence: 99%

“…This reflects global changes in DNA methylation as the tumor progresses in prostate cancer. This study demonstrated increased CD24 promoter methylation and elevated CD24 gene expression correlated with poorer survival of PC patients [ 64 ]. For breast and ovarian cancer, it was shown that CD24 can be expressed in tumor cells and promote immune evasion by interaction with the inhibitory receptor sialic-acid-binding Ig-like lectin 10 (Siglec-10) expressed on TAMs [ 66 ].…”

Section: The Role Of Dna Methylation In Prostate Carcinogenesismentioning

confidence: 99%

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers

Rafikova

Gilyazova

Enikeeva

et al. 2023

IJMS

View full text Add to dashboard Cite

Epidemiological data highlight prostate cancer as a significant global health issue, with high incidence and substantial impact on patients’ quality of life. The prevalence of this disease is associated with various factors, including age, heredity, and race. Recent research in prostate cancer genetics has identified several genetic variants that may be associated with an increased risk of developing the disease. However, despite the significance of these findings, genetic markers for prostate cancer are not currently utilized in clinical practice as reliable indicators of the disease. In addition to genetics, epigenetic alterations also play a crucial role in prostate cancer development. Aberrant DNA methylation, changes in chromatin structure, and microRNA (miRNA) expression are major epigenetic events that influence oncogenesis. Existing markers for prostate cancer, such as prostate-specific antigen (PSA), have limitations in terms of sensitivity and specificity. The cost of testing, follow-up procedures, and treatment for false-positive results and overdiagnosis contributes to the overall healthcare expenditure. Improving the effectiveness of prostate cancer diagnosis and prognosis requires either narrowing the risk group by identifying new genetic factors or enhancing the sensitivity and specificity of existing markers. Immunological biomarkers (both circulating and intra-tumoral), including markers of immune response and immune dysfunction, represent a potentially useful area of research for enhancing the diagnosis and prognosis of prostate cancer. Our review emphasizes the need for developing novel immunological biomarkers to improve the diagnosis, prognosis, and management of prostate cancer. We highlight the most recent achievements in the identification of biomarkers provided by circulating monocytes and tumor-associated macrophages (TAMs). We highlight that monocyte-derived and TAM-derived biomarkers can enable to establish the missing links between genetic predisposition, hormonal metabolism and immune responses in prostate cancer.

show abstract

“…There is a correlation between the transcription of AR and modulation of epigenetic inheritance. In addition, Tolkach et al [24] found that the promoter region of CD24 gene in PCa was hypermethylated, while the expression level of CD24 was increased, mainly because there was an ERG binding site between the methylation sites of CD24 promoter. Overexpression of ERG could upregulate CD24 expression, thereby promoting CD24 expression initiating the development of PCa.…”

Section: Molecular Mechanism Of Abnormal Dna Methylation and The Deve...mentioning

confidence: 99%

Research Progress of Abnormal DNA Methylation in the Development, Diagnosis, and Treatment of Prostate Cancer

Zhen Ren,

Ming Yu,

Xia

2023

ann urol oncol

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most common malignancy in men around the world. In recent years, studies have shown that the development of PCa is driven by epigenetic modifications to a great extent, mediated through abnormal DNA methylation. Aberrant methylation of DNA promoters leads to abnormal expression of genes that regulate the development and progression of PCa. In addition, the current diagnosis of PCa still relies on tissue invasiveness. Prostate biopsy is an invasive process whereas non-invasive liquid biopsy based measurement of abnormal DNA methylation is expected to become the future diagnostic method and may be established as a therapeutic target. This article reviews the progress on DNA methylation in the development, early diagnosis, prognosis, and treatment of PCa.

show abstract

DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer

Cited by 7 publications

References 51 publications

CD24-associated ceRNA network reveals prognostic biomarkers in breast carcinoma

CD24-associated ceRNA network reveals prognostic biomarkers in breast carcinoma

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers

Research Progress of Abnormal DNA Methylation in the Development, Diagnosis, and Treatment of Prostate Cancer

Contact Info

Product

Resources

About